LabCorp:
Growth hormone (GH) testing is primarily used to identify growth hormone deficiency and to help evaluate pituitary gland function, usually as a follow-up to other abnormal pituitary hormone test results.
GH testing is also used to detect excess GH and to help diagnose and monitor the treatment of acromegaly and gigantism.
Acromegaly : (IGF1 Serum, GH Serum)(LabCorp)
Circulating human growth hormone (GH) consists of several molecular isoforms. Increased proportion of circulating non-22K hGH and 20K hGH was reported in active acromegaly
The diagnosis and treatment decisions in acromegaly depend on the measurement of growth hormone (GH) and insulin-like growth factor I (IGF-I) levels. The occurrence of different GH isoforms in the serum, mainly 22K-hGH and 20K-hGH, is a source of heterogeneity of GH results measured by different immunoassays.
GH Serum is not a HPLC Lab Analysis
Here is a copy and paste from the labcorp website. Pay careful attention to the last paragraph where is states that the assay is calibrated to the WHO standard listed and 100% specific to the 22kda isoform:
Growth Hormone
Synonyms:
- Human Growth Hormone (hGH)
- Somatotropic Hormone (STH)
Test Number: 004275 CPT: 83003 (per specimen)
Related Information
- Growth Hormone Stimulation
- Growth Hormone Suppression Test for Acromegaly
- Multiple-specimen Testing
Specimen
Serum
Volume
0.8 mL
Minimum Volume
0.3 mL (
Note: This volume does
not allow for repeat testing.)
Container
Red-top tube or gel-barrier tube
Collection
If a red-top tube is used, transfer separated serum to a plastic transport tube.
Label tube with time of collection and patient's name.
Storage Instructions
Refrigerate
Stability
Temperature Period
Room temperature 7 days
Refrigerated 14 days
Frozen 14 days
Freeze/thaw cycles Stable x3
Patient Preparation
Random growth hormone sampling should be performed on fasting patients who have rested for at least 30 minutes prior to collection. Growth hormone stimulation and suppression protocols are described in the online Endocrine Appendices: Growth Hormone Stimulation and Growth Hormone Suppression.
Causes for Rejection
Gross hemolysis; lipemia; plasma specimen
Reference Interval
0.0−10.0 ng/mL
Use
Pituitary function test useful in the diagnosis of hypothalamic disorder, hypopituitarism, acromegaly, and ectopic growth hormone production by neoplasm
Limitations
A single fasting growth hormone (GH) level is of limited value. Secretion of GH is episodic and pulsatile. GH has a half-life of 20 to 25 minutes. Testing for growth hormone deficiency or excess is best done as part of a dynamic test involving specific stimuli (see the online Endocrine Appendices: Growth Hormone Stimulation and Growth Hormone Suppression). Insulin-like growth factor-1 can also be useful in assessing growth hormone status.
As in the case of any diagnostic procedure, results must be interpreted in conjunction with the patient's clinical presentation and other information available to the physician.
Methodology
Immunochemiluminometric assay (ICMA)
Additional Information
Human growth hormone (hGH) is a polypeptide hormone secreted from the acidophil cells of the anterior pituitary gland. Secretion is episodic and is associated with exercise, the onset of deep sleep or postprandially in response to falling glucose levels. Synthesis and release are under the control of hypothalamic releasing peptides and inhibitory peptides such as somatostatin. More recently, a gastric peptide, ghrelin, has been shown to also stimulate HGH secretion. The mediator of many hGH actions in the periphery, insulin-like growth-factor I (IGF-I) exerts an inhibitory effect through negative feedback mechanisms.1 hGH in circulation consists of several molecular isoforms, with 22,000 Dalton hGH being the most abundant, followed by a 20,000 Dalton hGH variant produced by alternative splicing. Approximately 50% of circulating hGH is bound to a high affinity binding protein.2 hGH is physiologically important in two main areas. Firstly, it has an integral role in skeletal growth which is well demonstrated in either excess or deficiency in childhood. The action of hGH in part is mediated through IGF-I as well as promoting protein synthesis and the uptake of amino acids into cells. Secondly, hGH influences intermediary metabolism by stimulating lipolysis and is antagonistic to the insulin-mediated uptake of glucose.3 hGH secretion is stimulated by hypoglycemia and suppressed by hyperglycemia.
In childhood, symptoms of hGH deficiency are retarded growth and dwarfism. Etiology is often unknown and an absolute or relative deficiency usually becomes apparent at about two years of age. Diagnosis can be confirmed by demonstrating low serum hGH which does not respond to stimulation tests. hGH deficiency is a major cause of severe short stature and diagnosis at an early stage is essential for successful therapy.4 Hyposecretion in adults usually becomes apparent during the laboratory investigation of hypopituitarism.5,6
Hypersecretion, commonly due to adenoma of the acidophil cells, is characterized by two conditions depending on whether it becomes apparent before or after fusion of the bony epiphyses. In childhood, excess hGH is characterized by gigantism. Heights of eight feet may be achieved and may also be associated with hypogonadism. In adults, acromegaly results, a condition characterized by progressive thickening of bone and soft tissue. Diagnosis is usually confirmed by dynamic function testing, which demonstrates a raised serum hGH level that does not fall in response to an oral glucose load.7 In conditions where there are nutritional disturbances, such as anorexia, starvation, renal failure, and hepatic cirrhosis, increased basal hGH levels may be found.
Recombinant hGH is available for treatment of hGH deficiency in both children and adults.4-6 hGH excess is treated by surgery, irradiation therapy, or somatostatin analogues.8,9 More recently, pegvisomant, a hGH receptor antagonist, which shares structural homology to hGH and competes with hGH for binding to the hGH receptor, has been developed.10
The IDS iSYS hGH assay conforms to the recommendations outlined in the recently published consensus statement on the standardization and evaluation of growth hormone assays.11 The assay is calibrated to the WHO International Standard for Somatropin from NIBSC, code 98/574.12 The assay is 100% specific for the 22 kDalton form of hGH and has no cross-reactivity with pegvisomant.13